Plant Growth Regulators
Estrogen Replacement Therapy
Amino Acid Oxidoreductases
Gene Expression Regulation, Plant
Prevalence of and factors associated with hormone replacement therapy counseling: results from the 1994 National Health Interview Survey. (1/121)OBJECTIVES: This study estimated the prevalence of and the factors associated with hormone replacement therapy (HRT) counseling. METHODS: We analyzed the responses of 3170 women, aged 40 to 60 years, from the 1994 National Health Interview Survey. RESULTS: The prevalence of HRT counseling was 43.6%. Women were more likely to report having received HRT counseling if they were White, older, more educated, had had a hysterectomy, had experienced menopausal symptoms, and had a regular source of care. CONCLUSIONS: More attention should be directed at counseling non-White women and women with less formal education. Reducing the barriers to having a regular source of care appears to increase the likelihood of receiving HRT counseling. (+info)
Longitudinal study of risk factors for coronary heart disease across the menopausal transition. (2/121)The patterns of change in blood lipids, diastolic blood pressure, body mass index, smoking and drinking behaviors, and exercise were examined in an ongoing longitudinal study from 1991 to 1995 of 150 middle-aged Melbourne, Australia, women as they passed through menopause. Changes in risk factors over time were examined with reference to time of the final menstrual period (FMP). Random effects models were fitted with adjustments for repeated measures and other covariates, including age. There were overall net increases between 3 years before and the 3 years after menopause of 0.25 mmol/liter for low density lipoprotein cholesterol, 0.05 mmol/liter for high density lipoprotein cholesterol (HDL cholesterol), 0.34 mmol/liter for triglycerides, 0.12 kg/m2 for body mass index, and 0.48 mmHg for diastolic pressure. The proportion of drinkers decreased by 13%, that of smokers increased by 17%, and that of women who exercised at least once a week increased by 6%. The only change dependent on the FMP was a significant decrease in HDL cholesterol (counterbalanced by a similar rise in HDL cholesterol in the year before the FMP), and the rate of decrease was maximal around 9 months after menses ceased, with an instantaneous estimate of slope of 0.55 mmol/liter per year. (+info)
High endogenous estradiol is associated with increased venous distensibility and clinical evidence of varicose veins in menopausal women. (3/121)OBJECTIVE: The purpose of this study was to determine if there is an association between elevated sex hormones (ie, serum estradiol, sex hormone binding globulin [SHBG], testosterone) and increased venous distension and clinical evidence of varicose veins in menopausal women. METHODS: Participants were 104 healthy volunteer menopausal women, aged 48 to 65 years, who were not undergoing hormonal treatment. Of these 104, 14 were excluded from analyses because their estradiol levels were compatible with a premenopausal condition (4), because they had missing values for insulin concentration (5), and because they did not show up at venous vessel examination (5). Patients underwent a physical examination to determine the presence of varicose veins; a venous strain-gauge plethysmographic examination to compute instrumental measures of venous distensibility; and laboratory analyses of blood so serum testosterone, estradiol, SHBG, glucose, and insulin could be measured. There were also prevalence ratios and odds ratios used to test the presence of an association between biochemical and instrumental variables. RESULTS: Serum levels of estradiol in the upper tertile of the frequency distribution were significantly associated with clinical evidence of varicose veins (prevalence odds ratios 3.6; 95% CI 1.1-11.6) and with increased lower limb venous distensibility (prevalence odds ratios 4.4; 95% CI 1.2-15.5). No association was found for SHBG and testosterone. CONCLUSIONS: Our finding that high serum levels of estradiol are associated with clinical evidence of varicose veins and instrumental measurements indicating increased venous distensibility in menopausal women suggests that endogenous estrogens may play a role in the development of this very common venous vessel abnormalities. (+info)
Effects of exercise experienced in the life stages on climacteric symptoms for females. (4/121)The purpose of this study is to investigate the effects of exercise experienced in the life stages on climacteric symptoms for females after menopause. Four-hundred and eight postmenopausal women completed a questionnaire. The results were as follows: (1) Mean age at menopause +/- standard deviation was 50.1 +/- 0.5 and did not show a significant relationship with the degree of exercise in the life stages. (2) The degree of climacteric symptoms had a significant relationship, or a tendency toward a significant relationship, with the degree of exercise in and after the 40's; and the greater the degree of exercise, the lesser the degree of climacteric symptoms. (3) Kupperman's index was found to be, or tended to be, significantly related to the degree of exercise in and after the 30's. Those who exercised heavily in their 30's showed a significantly lower Kupperman's index. Those who answered that they had exercised "moderately" in their "40's to menopause" and "menopause to 60 years old" tended to have the lowest index. (4) Exercise experience in the life stages was negatively correlated, in particular, to psychosomatic symptoms among the 3 climacteric symptom categories. This negative correlation tended to be higher in those who answered that they had done "less exercise" in and after their 30's. (5) A significant relationship was noted between the degree of exercise in the 30's and "weakness" in Kupperman's index, and between exercise in and after the 40's and "nervousness" and "melancholia". Therefore, it is suggested that exercising "moderately" from the subjective viewpoint in the climacteric period may alleviate psychosomatic symptoms. (+info)
Climacteric complaints in the community. (5/121)BACKGROUND: At the onset of the climacteric, healthy middle-aged women present with a variety of complaints, especially in general practice. In these first years of entering the menopause, vaginal blood loss alters from irregular periods to complete amenorrhoea. According to these different menstrual patterns, we can distinguish a pre-, peri- and postmenopausal phase. It could be useful to know whether specific climacteric complaints are related to these different phases. OBJECTIVE: The aim of this study was to investigate the relationship between climacteric complaints and the menstrual pattern during the menopausal transition in a population-based cross-sectional survey of healthy middle-aged women. METHODS: All women aged 47-54 years, living in the city of Eindhoven, were invited to participate in the Eindhoven Osteoporosis Study (EPOS); 6648 (78%) agreed to participate. All women completed a questionnaire concerning climacteric complaints. Climacteric status was defined by menstrual history. Odds ratios (ORs) were obtained for the relationship between climacteric status and climacteric complaints. Multiple logistic regression analysis was carried out, with climacteric status as the dependent variable. RESULTS: Of the 27 items in the questionnaire concerning climacteric complaints, seven were significantly different between all three climacteric phases (P: < 0.1). After multiple logistic regression analysis, comparing peri- and premenopause, only flushing (OR 5.9) was significantly different. Between post- and perimenopause, seven symptoms appeared to be different: three urogenital complaints [vaginal dryness (OR 1.6), vaginal discharge (OR 0.4) and pain during intercourse (OR 1.9)], three vasomotor symptoms [daytime sweating (OR 1.4), night-time sweating (OR 0.7) and flushing (OR 1.9)] and, finally, insomnia (OR 1.3). When comparing post- and premenopause, flushing (OR 13.4), insomnia (OR 2.1) and depressed mood (OR 0.6) were significantly different, in addition to three urogenital symptoms: vaginal dryness (OR 2.6), vaginal discharge (OR 0.3) and pain during intercourse (OR 2.1). CONCLUSION: The major findings of the study are that flushing is strongly associated with the transition from pre- to perimenopause, while urogenital complaints, daytime sweating and insomnia are more prominent in the transition from peri- to postmenopause. (+info)
Comparison between 1 year oral and transdermal oestradiol and sequential norethisterone acetate on circulating concentrations of leptin in postmenopausal women. (6/121)BACKGROUND: Oral and transdermal postmenopausal hormone replacement therapy (HRT) affects lipid and glucose metabolism differently, which is of significance in the release of leptin by adipocytes. Moreover, oestrogen and progesterone can stimulate leptin secretion in women of reproductive age. Therefore, we compared the effects of oral and transdermal oestrogen plus progestin regimen on plasma leptin in 38 healthy postmenopausal women with normal body mass index (BMI), who wished to use HRT to control incapacitating climacteric symptoms. METHODS: The women were randomized to treatment with oral HRT (2 mg oestradiol on days 1--12, 2 mg oestradiol plus 1 mg norethisterone acetate (NETA) on days 13--22, and 1 mg oestradiol on days 23--28, n = 19), or with transdermal HRT (50 microg/day of oestradiol on days 1--13, and 50 microg oestradiol plus 250 microg/day NETA on days 14--28, n = 19) for 1 year. Plasma samples were collected before and at oestradiol + NETA phase after 2, 6 and 12 months treatment and were assayed for leptin. RESULTS: The baseline leptin, ranging from 3.3 to 34.9 microg/l, was significantly associated with BMI (r = 0.78, P < 0.0001 ), but showed no difference between women in oral HRT (geometric mean 13.9 microg/l, 95% confidence interval (CI) 10.1--17.6 microg/l) or transdermal HRT group (geometric mean 12.0 microg/l, 95% CI 9.7--14.3 microg/l). Neither oral nor transdermal oestradiol + NETA caused any significant changes in plasma leptin (or BMI) after 2, 6, or 12 months of treatment. CONCLUSION: Leptin is an unsuitable factor to detect oestradiol + NETA-induced metabolic changes in postmenopausal women. (+info)
The andropause and memory loss: is there a link between androgen decline and dementia in the aging male? (7/121)Studies demonstrate a decline in androgens with age and this results in the andropause. The objective of this paper is to review the literature on hormonal changes that occur in the aging males and determine if there are associations between decreased testosterone, dehydroepiandrosterone (DHEA) and decreased cognitive function. Trials of androgen replacement and its impact on cognitive function will also be analyzed. Method of analysis will be by a thorough search of articles on MEDLINE, the Internet and major abstract databases. Results of the author's own research in 302 men of the association of memory loss as a symptom in the andropause will be presented. In addition, the authors open trial of testosterone replacement in hypogonadic men with Alzheimer's disease will also be presented. The results of the author's trial will be compared with other investigators. High endogenous testosterone level predicted better performance on visual spatial tests in several studies, but not in all studies. Likewise, testosterone replacement in hypogonadic patients improved cognitive functions in some but not all studies. Testosterone has also been shown to improve cognitive function in eugonadal men. Several studies have shown that declines in DHEA may contribute to Alzheimer's disease and the results of double blind studies with DHEA replacement and its effect on cognition will also be presented. In summary, there is still no consensus that androgen replacement is beneficial in cognitive decline but this option may prove promising in some patients. (+info)
Psychiatric morbidity and the menopause; screening of general population sample. (8/121)A survey of 539 women from the general population indicated a high prevalence of minor psychiatric illness in women aged 40-55 years. There was evidence of an increase in psychiatric morbidity occurring before the menopause and lasting until about one year after menstrual periods had ended. Vasomotor symptoms increased dramatically when periods stopped and persisted up to five years after the menopause. Both these features seemed to have a clear relation to the menopause but not the same relation. The findings suggested that further investigation of the relation between perimenopausal hormonal changes and psychiatric morbidity should be directed towards premenopausal women. Environmental factors, particularly in relation to children, seemed to be associated with increased psychiatric morbidity at this time of life. (+info)
The climacteric is a period of hormonal changes that occurs in women around the age of 45-55, known as menopause. During this time, the ovaries gradually stop producing estrogen and progesterone, which can lead to a variety of symptoms such as hot flashes, night sweats, mood swings, vaginal dryness, and sleep disturbances. The climacteric is a natural part of the aging process and is typically marked by the absence of menstruation for 12 consecutive months. In some cases, women may experience symptoms of the climacteric earlier or later than the average age of 45-55.
In the medical field, ethylenes are a group of organic compounds that contain a carbon-carbon double bond. They are commonly used as anesthetic gases and as propellants in inhalation anesthetics. Ethylenes are also used in the production of plastics, solvents, and other chemicals. Some examples of ethylenes include ethylene oxide, ethylene glycol, and ethylene dichloride. These compounds can have both therapeutic and toxic effects on the body, depending on the dose and duration of exposure.
Hot flashes are a common symptom experienced by women during menopause, characterized by a sudden feeling of warmth or heat that spreads over the face, neck, chest, and upper body. The sensation is often accompanied by sweating, redness of the skin, and a rapid heartbeat. Hot flashes can be brief, lasting only a few seconds, or longer, lasting several minutes. They can occur spontaneously or be triggered by factors such as stress, alcohol, or spicy foods. Hot flashes are caused by hormonal changes that occur during menopause, specifically a decrease in estrogen levels. They are a normal part of the menopausal transition for many women, but can also be a symptom of certain medical conditions or medications. Treatment options for hot flashes include lifestyle changes, hormone therapy, and medication.
Actinidia is a genus of flowering plants in the family Actinidiaceae, commonly known as kiwifruit. The genus includes several species of edible fruit, which are native to China and other parts of Asia. In the medical field, Actinidia species have been studied for their potential health benefits. Some studies have suggested that kiwifruit may have anti-inflammatory, antioxidant, and anti-cancer properties. The fruit is also a good source of vitamins C and K, as well as potassium and fiber. However, more research is needed to fully understand the potential health benefits of Actinidia species, and to determine the appropriate dosage and duration of use for any potential therapeutic applications. As with any dietary supplement or food, it is important to speak with a healthcare provider before using Actinidia or any other supplement.
Cimicifuga is a genus of plants in the family Ranunculaceae, commonly known as bugbane or black cohosh. Some species of Cimicifuga are used in traditional medicine to treat a variety of conditions, including menopausal symptoms, menstrual cramps, and anxiety. However, the safety and effectiveness of these uses have not been scientifically proven, and some species of Cimicifuga can be toxic if ingested in large amounts. In the medical field, Cimicifuga is not typically used as a treatment for any condition, and its use should be carefully considered and supervised by a healthcare professional.
Norpregnenes are a group of hormones that are derived from the progestogen hormone progesterone. They include the hormones allopregnanolone, dehydroepiandrosterone (DHEA), and androstenedione. These hormones play important roles in a variety of physiological processes, including the regulation of the menstrual cycle, the maintenance of pregnancy, and the regulation of mood and stress responses. They are also involved in the development and function of the brain and nervous system.
Cyclopropanes are a class of organic compounds that contain a three-membered ring of carbon atoms. They are often used in the medical field as a starting material for the synthesis of other drugs and as a component of certain medications. Cyclopropanes can also be used as a local anesthetic and as a treatment for certain types of cancer. They are typically administered intravenously or orally.
In the medical field, "Amino Acids, Cyclic" refers to a group of amino acids that have a ring structure in their side chain. These amino acids are also known as "cyclic amino acids" or "cyclic peptides." They are formed by the condensation of two or more amino acids through peptide bonds, resulting in a ring structure. Cyclic amino acids are found in various biological molecules, including peptides, proteins, and nucleic acids. They play important roles in various biological processes, such as enzyme catalysis, signal transduction, and gene regulation. Some examples of cyclic amino acids include proline, hydroxyproline, and ornithine. These amino acids have unique chemical and physical properties that make them useful in various medical applications, such as drug development, tissue engineering, and gene therapy.
Amino acid oxidoreductases are a group of enzymes that catalyze the oxidation of amino acids to produce various intermediates, including ammonia, carbon dioxide, and aldehydes or ketones. These enzymes play important roles in various metabolic pathways, including the catabolism of amino acids for energy production and the synthesis of other biomolecules. There are several types of amino acid oxidoreductases, including flavin-dependent enzymes, copper-containing enzymes, and iron-containing enzymes. Some examples of amino acid oxidoreductases include alanine aminotransferase, glutamate dehydrogenase, and ornithine transcarbamylase. In the medical field, amino acid oxidoreductases are often studied in the context of various diseases and disorders, such as liver disease, muscle wasting, and neurodegenerative diseases. Abnormalities in the activity or expression of these enzymes have been implicated in the pathogenesis of these conditions, and targeted therapies based on modulating the activity of amino acid oxidoreductases are being explored as potential treatments.
Paresthesia is a medical term that refers to a sensation of tingling, pricking, burning, or numbness in a part of the body. It can be caused by a variety of factors, including nerve damage, pressure on a nerve, poor circulation, or certain medical conditions such as diabetes or multiple sclerosis. Paresthesia can affect any part of the body, but is most commonly experienced in the hands, feet, arms, and legs. It is important to note that paresthesia can be a symptom of a more serious underlying condition, so it is important to consult a healthcare professional if you experience persistent or severe paresthesia.
Plant proteins are proteins that are derived from plants. They are an important source of dietary protein for many people and are a key component of a healthy diet. Plant proteins are found in a wide variety of plant-based foods, including legumes, nuts, seeds, grains, and vegetables. They are an important source of essential amino acids, which are the building blocks of proteins and are necessary for the growth and repair of tissues in the body. Plant proteins are also a good source of fiber, vitamins, and minerals, and are generally lower in saturated fat and cholesterol than animal-based proteins. In the medical field, plant proteins are often recommended as part of a healthy diet for people with certain medical conditions, such as heart disease, diabetes, and high blood pressure.
Uterine hemorrhage, also known as uterine bleeding, is a medical condition characterized by excessive bleeding from the uterus. It can occur in women of all ages and can be caused by a variety of factors, including pregnancy, childbirth, hormonal imbalances, uterine fibroids, uterine polyps, uterine cancer, and other medical conditions. Uterine hemorrhage can be classified as either acute or chronic. Acute uterine hemorrhage is a sudden and severe episode of bleeding that requires immediate medical attention, while chronic uterine hemorrhage is a persistent and gradual bleeding that occurs over a longer period of time. Symptoms of uterine hemorrhage may include heavy bleeding, abdominal pain, dizziness, weakness, and fainting. Treatment for uterine hemorrhage depends on the underlying cause and may include medications, surgery, or other medical interventions. In severe cases, hospitalization may be necessary to manage the bleeding and prevent complications.
Lyases are a class of enzymes that catalyze the cleavage of chemical bonds in a molecule, often resulting in the formation of two smaller molecules. They are involved in a variety of metabolic pathways, including the breakdown of amino acids, carbohydrates, and fatty acids. There are several types of lyases, including oxidoreductases, transferases, hydrolases, and ligases. Each type of lyase has a specific mechanism of action and is involved in different metabolic processes. In the medical field, lyases are often studied in the context of disease and drug development. For example, certain lyases are involved in the metabolism of drugs, and changes in the activity of these enzymes can affect the efficacy and toxicity of drugs. Additionally, some lyases are involved in the metabolism of harmful substances, such as toxins and carcinogens, and their activity can be targeted for therapeutic purposes.
International Menopause Society
Side effects of cyproterone acetate
Pharmacokinetics of progesterone
Pharmacokinetics of estradiol
Pudendal nerve entrapment
Hormone replacement therapy
WHO EMRO | Comparative study of climacteric symptoms in perimenopausal and postmenopausal women in Tabriz, Islamic Republic of...
Climacteric medicine: cornerstone for midlife health and wellness.
Abnormal (Dysfunctional) Uterine Bleeding: Practice Essentials, Background, Pathophysiology
Climacteric in anxiety: prevalence and associated factors
Climacteric (female) - ICD-10-CM Index to Diseases and Injuries
Homeopathic medicines for perimenopause, menopause and climacteric
Women's Health - Whole Health Library
Natural oestrogen in the female climacteric--influence on blood coagulation and fibrinolysis. | Herbal & Natural Medicine
Efficacy of Cimicifuga bRacemosa on climacteric complaints: a randomised study versus low-dose transdermal estradiol
Deciding about hormone therapy: MedlinePlus Medical Encyclopedia
Mir-183 functions as an oncogene via decreasing PTEN in breast cancer cells | Scientific Reports
Frontiers | The effects of combined amplitude and high-frequency vibration on physically inactive osteopenic postmenopausal...
Karin Kjellgren | Göteborgs universitet
Thieme E-Journals - Journal of Health and Allied Sciences NU / Abstract
Prevalence, impact and management of postmenopausal symptoms among postmenopausal women in Rwanda. | Climacteric;: 1-6, 2023...
New Drug Review 2021
Glonoin genitals etc symptoms by Boericke - ABC Homeopathy
A longitudinal study of vasomotor symptoms in Chinese women transitioning through menopause - International Menopause Society
The Case of "What Makes Sammy Run" - Deborah Walters
WTS database | WHO FCTC
Natrum Muriaticum relationships - ABC Homeopathy
Lisa Felder Race Results - UltraRunning Magazine
involutional melancholia | BehaveNet
Natural Approaches for Hot Flashes and other Symptoms of Menopause - Fairhaven Health
Browse Wordsmyth dictionary online as if using a print book | Wordsmyth
Venous thrombosis/thromboembolism risk and menopausal treatments - Australasian Menopause Society
- After the last menstruation - the menopause - these symptoms may accompany women and continue being present for an individual period of time of the climacteric. (homeopatsko-zdravljenje.si)
- It may be accompanied with different symptoms that were gathered in a questionnaire - Greene Climacteric Scale - for research purpose: 1. (homeopatsko-zdravljenje.si)
- Other climacteric symptoms (vasomotor and urogenital symptoms) as well as anxiety and depression, were evaluated at baseline and after 3 months. (unimore.it)
- this period is frequently termed the climacteric or perimenopause but is increasingly referred to as the menopausal transition. (medscape.com)
- A total of 200 women aged 45-55 years completed a Farsi version of the Greene climacteric scale. (who.int)
- CONCLUSIONS: CR (40 mg/day) may be a valid alternative to low-dose TTSE2 in the management of climacteric complaints in those women who cannot be treated with or just refuse conventional strategies. (unimore.it)
- In a research paper titled Management of distress during climacteric years by homeopathic therapy individualised homeopathy presented itself as an effective therapeutic modality in treating the burden of climacteric. (homeopatsko-zdravljenje.si)
- Nayak C. et al, Management of distress during climacteric years by homeopathic therapy, Journal of Alternative and Complimentary Medicine, Vol 11. (homeopatsko-zdravljenje.si)
- Climacteric may refer to: Climacteric (human), the time in most women's lives when menstrual periods stop permanently Climacteric (botany), a stage of fruit ripening Climacteric (journal), a journal published by Informa Healthcare Climacteric year, in astrology This disambiguation page lists articles associated with the title Climacteric. (wikipedia.org)
- Climacteric medicine: cornerstone for midlife health and wellness. (cdc.gov)
- For the assessment of the climacteric symptoms, the Blatt-Kupperman Index (BKI), the Menopause Rating Scale (MRS), and the Cervantes Scale (CS) were used. (nih.gov)
- A "menopause toolkit" that summarizes everything a clinician needs to know to identify menopause and prescribe treatment was introduced in an article published online July 6 in Climacteric . (medscape.com)
- The study, published in 2019 in the journal Climacteric, doesn't prove a cause and effect relationship, but it does suggest that practicing mindfulness could be a natural and noninvasive way for people experiencing menopause to manage anxiety and ease some symptoms. (sharecare.com)
- Hormonal therapy in climacteric women: compliance and its socioeconomic impact. (cdc.gov)
- Methodology: Transversal study, composed by 200 women aged 35-65 years, grouped according to the climacteric stage: premenopause (PRE), perimenopause (PERI) and postmenopause (POS). (usp.br)
- The participants of the clinical trial were 39 women at the age of 45-53 years with the climacteric syndrome diagnosis of light and moderate severity degree and 28 women at the age of 38-43 years with the exhausted ovary syndrome (early climacteric syndrome). (antiaging-systems.com)
- It was established that application of Zhenoluten in patients with mild and medium severity climacteric syndrome has resulted in improvement of the general condition, which manifested itself as a decrease in the number of hot flashes, better sleep and appetite, increase in working capacity (table 1). (antiaging-systems.com)
- Age-related or pathological changes of the ovarian function are characterized by development of complicated symptom complex with signs of neuropsychic, vasomotor and metabolic-endocrine disorders, united in a concept of "climacteric syndrome" (1, 4, 5). (antiaging-systems.com)
- The assessments were made by Greene Climacteric Scale, Perceived Stress Scale, and Eysenck's Personality Inventory before and after the intervention. (medscape.com)
- This evolutionary crisis is a life process that usually happens at the same time as climacteric, and roughly matches the years when half of life occurs. (menopausia.care)
- It then continues with a thumbnail description of the seven-year cyclical climacteric pattern of individual human development. (booksamillion.com)